References
- Alas S, Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clinical Cancer Research 2003; 9: 316–326
- Levine R L, Wadleigh M, Cools J, Ebert B L, Wernig G, Huntly B J. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397
- James C, Ugo V, Le Couedic J P, Staerk J, Delhommeau F, Lacout C. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–1148
- Steensma D P, Dewald G W, Lasho T L, Powell H L, McClure R F, Levine R L. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both ‘atypical’ myeloproliferative disorders and the myelodysplastic syndrome. Blood 2005; 106: 1207–1209
- Gschwind A, Fischer O M, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Natural Reviews in Cancer 2004; 4: 361–370
- Wessendorf S, Schwaenen C, Kohlhammer H, Kienle D, Wrobel G, Barth T F. Hidden gene amplifications in aggressive B-cell non-Hodgkin lymphomas detected by microarray-based comparative genomic hybridization. Oncogene 2003; 22: 1425–1429
- Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Research 2005; 65: 2662–2667